Genetic scissors snip away at sickle cell.

The first CRISPR gene editing therapy has been approved to treat sickle cell disease, heralding a new era of transformative genomic medicine. By precisely editing a single gene in a patient's stem cells, scientists can override the mutation that causes debilitating sickle cell pain crises. Though complex and costly at $2 million per treatment, the approach offers hope of a "one-and-done" cure and could pave the way for treating numerous other genetic diseases.

Read the full article on Wired.

----